ZLAB — Zai Lab Ltd

Nasdaq · Health Care · Pharmaceuticals · CIK 1704292 · China
Last close
$25.64
Market Cap
$2.88B
52W High
$27.50
52W Low
$16.26
ADV30
1,041,209
Next earnings
2026-11-05
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 106,311,000 58,149,000 -76,489,000 -50,825,000 1,074,793,000 607,522,000 467,756,000
Mar 2026 99,611,000 61,276,000 -69,279,000 -51,016,000 1,095,737,000 651,316,000 433,756,000
Dec 2025 127,597,000 65,266,000 -68,264,000 -50,409,000 1,172,384,000 679,573,000 456,884,000
Sep 2025 116,095,000 69,212,000 -47,968,000 -35,963,000 1,158,940,000 717,155,000 398,995,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-133,384,000
Investing CF
$-39,050,000
Financing CF
$44,641,000
CapEx
$-29,134,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.80
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,730,461,000
Inventory
$90,890,000
Receivables
$72,990,000
ST Investments
$10,000,000
EBIT TTM
$-184,737,000
Pretax Income TTM
$-190,722,000
Interest Exp TTM
$5,985,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$449,614,016
EBITDA
$-248,168,000
Free Cash Flow
$-83,963,752
Enterprise Value
$2,515,560,192
Total Cash
$617,521,984
Total Debt
$254,576,000
Shares Out
112,266,228
Trailing EPS
$-1.70
Book Value
$5.96
ROE
-26.9%
ROA
-14.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 460,156,000 -223,572,000 -175,537,000 1,172,384,000 456,884,000 -150,789,000
Dec 2024 398,988,000 -273,947,000 -257,103,000 1,185,753,000 344,855,000 -214,869,000
Dec 2023 266,719,000 -374,140,000 -334,620,000 1,036,295,000 240,177,000 -198,178,000
Dec 2022 215,040,000 -392,886,000 -443,286,000 1,220,140,000 174,545,000 -367,642,000

TTM Snapshot

Revenues TTM
$102,265,000
NetIncome TTM
$-41,671,000
OpCashFlow TTM
$0
Assets (Latest)
$1,185,753,000
Forward EPS
$-2.06

Max Pain — expiry 2026-12-18

max pain strike: $22.50 · spot: $25.64 · call oi: 362 · put oi: 2,744
Expected Move to 2026-12-18: ±$11.05 (43.10%) — implied range $14.59$36.69 · ATM straddle on $25.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
SLS SELLAS Life Sciences Group, Inc. $2.89B $14.32
ALMS ALUMIS INC. $2.98B $23.03
ATAI AtaiBeckley Inc. $2.74B $7.38
NRIX Nurix Therapeutics, Inc. $2.73B $26.27
VRDN Viridian Therapeutics, Inc.\DE $2.72B $24.02

News headlines (Yahoo Finance, 1h cache)

Global DLL3 Targeted Therapies Market 2026-2030: Profiles Amgen, Zai Lab, Boehringer Ingelheim and Phanes Therapeutics
2026-08-20 15:30 · Yahoo
Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer
2026-08-18 07:00 · Yahoo
Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript
2026-08-13 13:58 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Marginally Higher in Thursday Trading
2026-08-13 14:44 · Yahoo
Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?
2026-08-20 22:27 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading
2026-08-19 14:46 · Yahoo
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
2026-08-17 10:00 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
2026-08-11 14:43 · Yahoo
Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?
2026-08-10 02:08 · Yahoo
Zai Lab (ZLAB) Rebounds Following Earnings While Its Undervalued Narrative Faces A Fresh Test
2026-08-09 17:09 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.